PANTHERx Rare Announces Exciting Leadership Changes: New President and Key Hire
PITTSBURGH, June 21, 2023 /PRNewswire/ — PANTHERx Rare, the nation’s leading rare disease pharmacy, is excited...
Read More
PANTHERx Rare Pharmacy Expands Services to Include Dispensing AYVAKIT® (avapritinib) for the Expanded Approval for Treatment of Indolent Systemic Mastocytosis (ISM).
June 19, 2023 Blueprint Medicines recently announced the approval of AYVAKIT® (avapritinib) for the expanded indication of...
Read More
PANTHERx Rare Pharmacy Expands Services to Include Dispensing AYVAKIT® (avapritinib) for the Expanded Approval for Treatment of Indolent Systemic Mastocytosis (ISM).
Blueprint Medicines recently announced the approval of AYVAKIT® (avapritinib) for the expanded indication of adults with...
Read More
PANTHERx® Rare Announces Partnership with Biocodex for the Distribution of DIACOMIT® (stiripentol) for the Treatment of Seizures Associated with Dravet Syndrome in Patients 2 Years of Age and Older Taking Clobazam
Read the Official PANTHERx Press Release. PANTHERx Rare announces that it has been selected by Biocodex as their new exclusive...
Read More
PANTHERx Rare Celebrates Fifth Patient Choice Award Win
Read the Official PANTHERx Press Release. For a fifth time, PANTHERx Rare has been recognized as the winner of the annual,...
Read More
PANTHERx® Rare Selected by Aadi Bioscience to Distribute FYARRO™ (sirolimus protein-bound particles for injectable suspension) (albumin-bound) for advanced malignant perivascular epithelioid cell neoplasm (PEComa)
Read the Official PANTHERx Press Release. PANTHERx Rare announces that it has been selected by Aadi Bioscience as the exclusive...
Read More
